Chemogenetic epilepsy trial reports fewer seizures in three patients
Text
Early human results need larger studies.
Three refractory-epilepsy patients had 92.6% fewer seizures on average in a chemogenetic trial reported by NEJM.
It paired hippocampal chemogenetic therapy with low-dose clozapine.
CIBR calls it a first-in-human chemogenetic neuromodulation study.
Larger trials must test whether the benefit generalizes and remains safe over time.
Original source published: Journal issue and CIBR announcement, November 5, 2026
Share this article
What do you think of this story?
Anonymous feedback, up to 5 reactions per article.
Anonymous comments
Share your thoughts without signing in.
Discuss the technology and the story. Hate, politics and war, threats, abuse, personal accusations, sexual content, ads, links and personal information are not allowed.
No comments yet. Be the first to share.